PURE Bioscience Inc. (OTC: PURE) Stock Continues To Trend Lower: Here is Why

This morning most investors are going to be looking into those companies that had come into focus one way or another last Friday. One such company could be PURE Bioscience Inc. (OTC: PURE), which attracted the interest of investors on Friday following a key announcement.

New Distribution Agreement

On November 11, the company hit the news cycle after PURE Bioscience announced that it entered into a distribution agreement spanning several years with Quip Laboratories Inc. The distribution agreement in question had been signed with the view of selling and purchasing SDC products under the provisions of some special terms and conditions.

In the news release, it was also noted that Quip Laboratories was a noted leader in products related to pharmaceutical production, biomedical research, food processing space, and companion animal care. The partnership would make the products from PURE Bioscience more accessible while maintaining safety and quality standards.

Further Information

The company also noted in the news release that the multi-year partnership would also allow the PURE Bioscience and Quip Laboratories to pool their knowledge, expertise, and experience.

As a consequence, the clients and customers would be delivered a higher level of service, which would be characterized by adherence to the greatest compliance and safety standards. It would be interesting to see if the PURE Bioscience stock gets any traction this morning in light of the latest deal.

Key Quote

“We are incredibly excited to partner with Quip Labs,” said Tim Steffensmeier, VP of Sales at PURE. “This agreement represents a significant step forward in our growth strategy, allowing us to leverage Quip Lab’s expertise and established network. Together, we will provide even more comprehensive solutions that meet the biomedical, pharmaceutical, and food processing industries’ unique needs while enhancing laboratory animal care.”